Lurasidone-induced hyperosmolar hyperglycemic syndrome: A case report

Neuropsychopharmacol Rep. 2022 Sep;42(3):377-379. doi: 10.1002/npr2.12259. Epub 2022 May 24.

Abstract

Introduction: Lurasidone has few metabolic adverse effects and is recommended as an alternative when other antipsychotic drugs considerably increase body weight or blood sugar concentrations.

Case presentation: An 81-year-old man with bipolar disorder developed hyperosmolar hyperglycemic syndrome as a side effect of lurasidone. Routine monitoring of blood glucose concentrations led to the early detection and treatment of this disease, preventing life-threatening complications.

Discussion and conclusion: We describe a rare case of lurasidone-induced hyperosmolar hyperglycemic syndrome. The mortality rate of this syndrome is estimated to be up to 20%. This rate is significantly higher than that of diabetic ketoacidosis (currently <2%). Although lurasidone is considered to have a low risk of raising blood glucose concentrations, symptoms of hyperglycemia must be evaluated and blood glucose concentrations should be monitored regularly.

Keywords: Drug-related side effects and adverse reactions; Hyperglycemia; Hyperglycemic hyperosmolar nonketotic coma; Lurasidone hydrochloride.; bipolar disorder.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Antipsychotic Agents* / adverse effects
  • Blood Glucose / metabolism
  • Diabetic Ketoacidosis* / diagnosis
  • Diabetic Ketoacidosis* / etiology
  • Diabetic Ketoacidosis* / therapy
  • Humans
  • Hyperglycemic Hyperosmolar Nonketotic Coma* / chemically induced
  • Hyperglycemic Hyperosmolar Nonketotic Coma* / diagnosis
  • Lurasidone Hydrochloride / adverse effects
  • Male

Substances

  • Antipsychotic Agents
  • Blood Glucose
  • Lurasidone Hydrochloride